Bringing Medical Devices and IVDs to Egypt: A Practical Regulatory Roadmap for Foreign Manufacturers

Egypt is one of the region’s largest healthcare markets by population, with the World Bank estimating a population of about 118.4 million in 2025.¹ For international medical-device and in-vitro diagnostic (IVD) manufacturers, that scale creates a significant commercial opportunity - but access depends on understanding a regulatory system that is increasingly formalised, digital and documentation-led.

The Egyptian Drug Authority (EDA) is the national authority responsible for regulating the quality, effectiveness and safety of pharmaceutical products and medical devices. Its Central Administration of Medical Devices publishes the core registration, import-approval and post-market guidance used by applicants.²

Egypt’s wider regulatory system has also continued to mature. The EDA has achieved World Health Organization Maturity Level 3 for medicines and vaccines, and in 2026 it continued work toward Maturity Level 4. That recognition does not itself constitute a medical-device approval, but it reflects the broader institutional development of Egypt’s national regulatory authority.³

Start with the product, not the application form

A foreign manufacturer should begin by defining exactly what it intends to place on the Egyptian market. Regulatory treatment depends on the product type, intended use, sterility, risk classification, quality certificates and the regulatory route under which the product is being submitted.

For medical devices holding international quality certificates, the EDA’s September 2025 registration guideline sets out separate procedures for sterile and non-sterile devices and addresses different risk classes, system registrations and bundling arrangements.⁴ The same guideline identifies the registration applicant as an importing company, a local facility or a scientific office.⁴

For IVDs and laboratory or diagnostic equipment, separate EDA guidance governs import approvals and registration requirements. Since late 2025, applications for diagnostic reagents and laboratory devices, including relevant import approvals and registration files, have been routed through the MeDevice electronic platform.⁵

A practical regulatory pathway

Stage	Key question	Why it matters
1. Product scoping	What exactly is the product, intended use and classification?	The route and evidence requirements differ by device type and risk.
2. Regulatory pathway	Which EDA guideline and submission route applies?	Medical devices, diagnostic reagents and laboratory equipment do not all follow the same procedure.
3. Local structure	Who will be the registration applicant and who will manage local representation?	The applicant and representation model affect documentation, accountability and ongoing maintenance.
4. Dossier readiness	Are the quality, conformity, free-sale and technical documents complete?	Incomplete or inconsistent files create avoidable queries and delays.
5. Electronic submission	Which MeDevice service and workflow applies?	EDA increasingly receives device and IVD applications electronically.
6. Import pathway	What import approval or licensed importer arrangement is required?	Registration and importation are related but not identical regulatory steps.
7. Lifecycle management	Who tracks renewals, variations, vigilance and post-market obligations?	Market access continues after the initial approval.

1. Determine the applicable classification and evidence base

The first regulatory task is to establish the product’s intended use, classification and supporting quality framework. Under the current EDA medical-device guidance, documents used in registration may include declarations of conformity, CE documentation, ISO 13485 certification and Free Sale Certificates, depending on the device and route.⁴

The EDA has also continued to update how international regulatory evidence is accepted. In March 2026, the Authority announced that, for medical devices and diagnostic reagents, a U.S. FDA Certificate to Foreign Government may in certain circumstances be submitted where a Free Sale Certificate from a European reference country is unavailable, together with the other required quality documents.⁶

The practical lesson is that a dossier should not be assembled as a generic global package. The evidence must be mapped against the current Egyptian checklist for the specific product.

2. Decide who will act locally

Foreign manufacturers need a clear local regulatory structure. Depending on the product and business model, the relevant parties can include a registration applicant, importer, distributor and/or licensed scientific office.

EDA’s scientific-office framework expressly recognises an “Authorized Scientific Office” affiliated with a local company and authorised by a foreign company in relation to that foreign company’s pharmaceutical products or medical devices. The guide also states that, by decision of the EDA Chairman, a scientific office may be authorised to register medical devices in its own name and on its own account where the applicable conditions are met.⁷

This means regulatory representation and commercial distribution should be designed deliberately. The company that communicates with the regulator, the entity that holds or submits the registration, and the entity that physically imports or distributes products may have different roles.

3. Understand the scientific-office requirements before relying on the structure

Where a scientific-office model is relevant, the EDA licensing guide is detailed. An authorised scientific office requires a local company with a commercial register and a formal authorisation from the foreign company. The authorisation is required to be authenticated through the Chamber of Commerce in the foreign country and then the Egyptian Embassy in that country.⁷

The guide also requires a medical-sample store of at least 25 square metres, identifies a qualified Scientific Office Manager and requires a full-time pharmacist in charge of the sample store. In specified circumstances, the same full-time pharmacist may hold both roles where the sample store is located within the scientific-office premises.⁷

These are establishment-level requirements, not simply paperwork attached to a product registration. Manufacturers therefore need to distinguish between the regulatory documents for the product and the licensing requirements for the local representative structure.

4. Build the dossier around the Egyptian checklist

The quality of the initial submission has a direct impact on the amount of regulatory follow-up required. The September 2025 medical-device guideline provides a detailed list of registration documents and separate appendices for different device circumstances.⁴

For non-sterile imported Class IIa, IIb and III devices using the initial-file route, the EDA identifies core documents including a declaration of conformity, CE certificate, ISO 13485:2016 and Free Sale Certificates under the conditions specified in the guideline.⁴

For laboratory and diagnostic equipment, the applicable guidance similarly distinguishes between device categories and sets different combinations of declarations, Free Sale Certificates, ISO certificates and conformity documents.⁸

A useful pre-submission exercise is therefore a technical-documentation gap assessment: compare every available manufacturer document against the current Egyptian requirement, record missing or expiring documents, identify documents needing legalisation, and resolve inconsistent manufacturer or supplier names before submission.

5. Treat the MeDevice platform as part of the regulatory process

EDA has progressively moved medical-device services onto the MeDevice electronic platform. The 2025 medical-device registration guideline requires electronic submission through the platform, while EDA’s November 2025 notice confirmed exclusive MeDevice submission for diagnostic-reagent and laboratory-device import approvals and registration files.⁴⁵

Digital submission makes document control more important, not less. File names, document versions, signatures, legal entities, product descriptions and uploaded certificates need to remain consistent across the electronic record.

6. Separate registration from import approval

A registration pathway does not remove the need to consider import controls. EDA maintains specific guidelines for import approvals for medical devices, medical equipment and laboratory and diagnostic equipment.²

For laboratory and diagnostic equipment, the 2025 guidance states that applications are submitted through MeDevice, reviewed electronically and, once the file is fulfilled, an import approval is issued with the relevant invoice attached.⁸

Manufacturers should therefore map the entire supply chain: who supplies the product, who appears on the invoice, which local company is licensed to import, whether distributor or agency documentation is needed, and how the product registration and import approval interact.

7. Plan for regulatory maintenance from day one

Regulatory work continues after initial registration. Medical-device businesses need to plan for variations, re-registration or renewal, changes to certificates, vigilance, import approvals and other lifecycle events.

EDA publishes dedicated guidance for changes to medical-device registration data and for vigilance and safety processes. It also issued updated guidance in 2026 relating to Unique Device Identification (UDI) requirements.² The implication is that regulatory ownership should remain active throughout the commercial life of the product rather than being treated as a one-off filing exercise.

Why Egypt’s regulatory environment deserves attention

Egypt combines a very large domestic market with a healthcare system that is continuing to expand. The Universal Health Insurance Authority reported more than 5.4 million beneficiaries covered under the system by June 2026.⁹ At the same time, the EDA has increased its participation in international and African regulatory cooperation, including work through the African Medical Devices Forum and broader regulatory-convergence initiatives.¹⁰

For manufacturers, this strengthens the case for treating Egypt as a strategic regulatory market rather than an afterthought in a regional launch plan. The strongest approach is to build an Egypt-specific pathway early: define the product, identify the correct applicant and local structure, prepare the evidence against the current EDA checklist, and maintain clear ownership of the registration lifecycle.

A final checklist for foreign manufacturers

• Confirm the product category, intended use and risk classification.

• Identify the current EDA guideline applicable to the product.

• Decide who will act as registration applicant and local representative.

• Confirm the importer/distributor structure where physical importation is required.

• Review CE, ISO 13485, Free Sale Certificate and other market-authorisation evidence.

• Complete a technical-documentation gap assessment before submission.

• Check which documents require legalisation or authentication.

• Prepare the submission for the MeDevice electronic workflow.

• Assign responsibility for EDA correspondence, queries and document updates.

• Plan in advance for variations, renewals/re-registration, import approvals and vigilance.

Egypt’s medical-device framework is detailed, but it is navigable when the regulatory pathway is designed before the commercial launch. For foreign manufacturers, the quality of local preparation is often as important as the quality of the global dossier.

This article is general regulatory information and does not constitute legal, regulatory or commercial advice. Requirements should be verified against the latest EDA guidance for the specific device or IVD.

References

1. World Bank, World Development Indicators - Egypt population, 2025.

2. Egyptian Drug Authority, Central Administration of Medical Devices - Regulatory Guidelines, accessed September 2026.

3. Egyptian Drug Authority, International Quality Accreditations / WHO Global Benchmarking Tool; and EDA public consultation on progression toward ML4, 2026.

4. Egyptian Drug Authority, Regulatory Guideline for Procedures of Registering Imported and Local Medical Devices Holding International Quality Certificates, Version 02, September 2025.

5. Egyptian Drug Authority, Notice on Import Approvals and Registration Files of Diagnostic Reagents and Laboratory Devices via MeDevice, 27 November 2025.

6. Egyptian Drug Authority, Announcement on Accreditation Procedures under European Regulations for Medical Devices and IVDs, 11 March 2026.

7. Egyptian Drug Authority, Organizational Guide for the Procedures of Licensing Scientific Offices, Code EDREX: GL.CAO.017, Version 1/2024, current EDA publication.

8. Egyptian Drug Authority, Regulatory Guideline for the Procedures and Rules of Obtaining Import Approvals for Laboratory and Diagnostic Equipment and Imported Accessories, Version 02/2025.

9. Universal Health Insurance Authority, coverage and performance update, 10 June 2026.

10. Egyptian Drug Authority, Foreign Affairs and International Memberships - African Medical Devices Forum and African regulatory cooperation.